Results from the Aspreva Lupus Management Study
Dr. David Wofsy is Professor of Medicine in the Department of Rheumatology at the University of California, San Francisco Medical Center. Dr. Wofsy is also Chief of Rheumatology at the VA Medical Center in San Francisco, as well as a member of the Lupus Foundation of America Medical-Scientific Advisory Council. The Aspreva Lupus Management Study (ALMS) was a two part clinical study that compared Mycophenolate Mofetil (MMF), marketed under the brand name CellCept(R), to other drugs for the treatment of lupus kidney disease, or lupus nephritis (LN). The data presented by Dr. Wolfsy at the Ninth International Congress on Lupus in Vancouver, British Columbia, was for the second part of the ALMS study, which looked at long term maintenance of LN. The study showed that Mycophenolate Mofetil, or CellCept(R), was superior to to azathioprine (standard care) as a long-term treatment for lupus nephritis. The results are very encouraging as MMF was better tolerated by patients with fewer side effects.
Sheila Shaw, Lupus Survivor, Takes Back Control
Video Rating: 3 / 5 Learn basic information on kidney disease from the experts at Kidney Disease Info Blog.
Related Posts:
Orignal From: Results from the Aspreva Lupus Management Study
No comments:
Post a Comment